论文部分内容阅读
目的:探讨替格瑞洛对经皮冠状动脉介入术(PCI)术后血清IL-6、TNF-α水平变化。方法:选取2014年4月至2016年3月在我院行PCI治疗的患者180例,将患者随机分为观察组(n=98)和对照组(n=82),观察组口服替格瑞洛,对照组口服氯吡格雷,检测两组治疗前后IL-6、TNF-α、高敏C反应蛋白(hs-CRP)和可溶性白细胞分化抗原40配体(s CD40L)以及血小板最大聚集率(MPAR)。结果:观察组术后1 d、7 d和28 d IL-6、TNF-α、hs-CRP和s CD40L均明显低于对照组(P<0.05);观察组治疗后1 d、7 d和28 d MPAR分别为(54.10±12.51)%、(41.03±13.20)%和(30.81±9.78)%,明显低于对照组(P<0.05);观察组和对照组主要心血管不良事件发生率分别为1.02%和2.44%,差异比较无统计学意义(P>0.05)。结论:替格瑞洛能显著降低PCI术后血清炎症因子水平,抗血小板聚集和血管保护作用较好。
Objective: To investigate the effect of ticagrelor on the levels of serum IL-6 and TNF-α after percutaneous coronary intervention (PCI). Methods: A total of 180 patients undergoing PCI from April 2014 to March 2016 in our hospital were enrolled. Patients were randomly divided into observation group (n = 98) and control group (n = 82) The control group received oral clopidogrel, and the levels of IL-6, TNF-α, hs-CRP and sCD40L and the ratio of platelet aggregation to MPAR ). Results: The levels of IL-6, TNF-α, hs-CRP and sCD40L in the observation group at 1 d, 7 d and 28 d after operation were significantly lower than those in the control group (P <0.05) (54.10 ± 12.51)%, (41.03 ± 13.20)% and (30.81 ± 9.78)%, respectively, which were significantly lower than those of control group on 28th day (P <0.05). The incidences of major cardiovascular adverse events in observation group and control group were 1.02% and 2.44%, respectively, with no significant difference (P> 0.05). Conclusion: Ticagrelor can significantly reduce the level of serum inflammatory cytokines after PCI, and has good anti-platelet aggregation and vascular protection.